AntoXa
AntoXa Corporation is a Canadian biopharmaceutical company dedicated to developing medical countermeasures to protect military and civilian personnel from biological and chemical agents, as well as outbreaks of naturally occurring infectious diseases. They focus on producing high-value biopharmaceuticals using their proprietary _vivo_ XPRESS® plant-based manufacturing platform, which offers rapid, low-cost, and scalable production of therapeutics for biodefense and infectious diseases.
Industries
Nr. of Employees
small (1-50)
Products
PhD9 (anti-ricin monoclonal antibody candidate)
A monoclonal antibody developed as a therapeutic antidote to ricin exposure; plant-based manufacturing process and antibody have been studied in vitro and in vivo with results reported as comparable to mammalian-produced versions.
Recombinant butyrylcholinesterase (BuChE)
High-yield, plant-made recombinant BuChE being developed as a prophylactic and therapeutic countermeasure to organophosphate nerve agents (e.g., sarin, soman); safety evaluated in animal models.
Recombinant human hemopexin (enzyme drug candidate)
Plant-produced recombinant human hemopexin being investigated to reverse lung and mitochondrial injury caused by toxic halogen exposure (chlorine gas) and potentially for complications of sickle cell disease; preclinical data cited.
Recombinant human ACE2 candidates (SARS-CoV-2 decoy proteins)
Plant-expressed recombinant human ACE2 candidates for potential prophylactic or early-stage treatment of SARS-CoV-2 infection; program supported under contract with Defence Research and Development Canada with activities to express, purify and characterize ACE2 candidates.
PhD9 (anti-ricin monoclonal antibody candidate)
A monoclonal antibody developed as a therapeutic antidote to ricin exposure; plant-based manufacturing process and antibody have been studied in vitro and in vivo with results reported as comparable to mammalian-produced versions.
Recombinant butyrylcholinesterase (BuChE)
High-yield, plant-made recombinant BuChE being developed as a prophylactic and therapeutic countermeasure to organophosphate nerve agents (e.g., sarin, soman); safety evaluated in animal models.
Recombinant human hemopexin (enzyme drug candidate)
Plant-produced recombinant human hemopexin being investigated to reverse lung and mitochondrial injury caused by toxic halogen exposure (chlorine gas) and potentially for complications of sickle cell disease; preclinical data cited.
Recombinant human ACE2 candidates (SARS-CoV-2 decoy proteins)
Plant-expressed recombinant human ACE2 candidates for potential prophylactic or early-stage treatment of SARS-CoV-2 infection; program supported under contract with Defence Research and Development Canada with activities to express, purify and characterize ACE2 candidates.
Services
Project-based development and production of recombinant proteins and antibodies for government and industry clients, including process development and supply for biodefense programs.
Transfer of plant-based manufacturing knowhow and processes to external GMP manufacturers and partnerships to enable clinical‑grade production and regulatory submission support.
Project-based development and production of recombinant proteins and antibodies for government and industry clients, including process development and supply for biodefense programs.
Transfer of plant-based manufacturing knowhow and processes to external GMP manufacturers and partnerships to enable clinical‑grade production and regulatory submission support.
Expertise Areas
- Plant molecular farming
- Biodefense therapeutics
- Recombinant protein expression and purification
- Glycoengineering for therapeutic proteins
Key Technologies
- Plant molecular farming (tobacco-based expression)
- Stable glyco-modified Nicotiana benthamiana lines
- Transient and stable plant expression systems
- Recombinant protein purification workflows
News & Updates
AntoXa Corporation and SwiftPharma will present their development and commercialization of a plant-made antibody against ricin exposure to the NATO Biological Defense Medical Expert Panel in Tournai, Belgium.
AntoXa received a patent for its plant-based manufacturing process to produce an antibody for ricin treatment, developed under license from Defence Research & Development Canada.
AntoXa Corporation and SwiftPharma will present their development and commercialization of a plant-made antibody against ricin exposure to the NATO Biological Defense Medical Expert Panel in Tournai, Belgium.
AntoXa received a patent for its plant-based manufacturing process to produce an antibody for ricin treatment, developed under license from Defence Research & Development Canada.